BioMarin CBO James Sabry at #JPM24 (Brian Benton Photography)
January 23, 2025 10:00 AM EST
Deals

Bio­Marin turns to ex-Roche deal­mak­er James Sabry to build ‘next ver­sion’ of 27-year-old com­pa­ny

Andrew Dunn

Senior Biopharma Correspondent

SAN FRAN­CIS­CO — Not many biotechs sur­vive be­yond 25 years, let alone get mul­ti­ple drugs ap­proved and turn a prof­it.

Bio­Marin Phar­ma­ceu­ti­cal has done all …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pur­due, Sack­lers reach new $7.4B opi­oid set­tle­ment af­ter SCO­TUS re­jec­tion

As an­oth­er Trump term gets un­der­way, phar­ma ad­vi­sors get com­fort­able with un­cer­tain­ty

Sam­sung Bio hits rev­enue high, se­cures largest con­tract to date

Ab­b­Vie part­ners with Neo­morph in lat­est mol­e­c­u­lar glue deal

Up­dat­ed: Bio­gen makes cuts across its re­search unit, shift­ing fo­cus to ‘ex­ter­nal op­por­tu­ni­ties’

sponsored

Fu­el­ing More Break­throughs: Man­u­fac­tur­ing In­no­va­tion to Ex­pand Gene Ther­a­py’s Reach

A service from the Financial Times